The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.
Royal Bank of Canada reaffirmed their outperform rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report published on Wednesday morning,Benzinga reports. They currently have a ...
If you have sleep apnea, it’s important to get treatment, which can include lifestyle changes, mouthpieces, surgery and breathing devices. You may have a sleep disorder if you: Have difficulty falling ...
The Driver and Vehicle Licensing Agency (DVLA) is warning drivers about various medical conditions that could affect their ability to drive. It urges individuals to declare any listed conditions to ...
Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at ...
Selvaraju highlighted Axsome earlier in the week as a Top Pick within their coverage universe, reiterating the Buy rating and emphasizing the company's strengthened position following the FDA's green ...
However, if you have a medical condition that affects your driving but don't voluntarily give up your licence, you must inform the DVLA, which will decide if you can continue holding a driving licence ...
Cantor Fitzgerald upgraded shares of Zevra Therapeutics (NASDAQ:ZVRA – Free Report) to a strong-buy rating in a research note issued to investors on Wednesday,Zacks.com reports. Other equities ...